HomeCompareELXMF vs PLD

ELXMF vs PLD: Dividend Comparison 2026

ELXMF yields 105263.16% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ELXMF wins by $8.064713171987811e+26M in total portfolio value
10 years
ELXMF
ELXMF
● Live price
105263.16%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.064713171987811e+26M
Annual income
$804,966,999,868,734,400,000,000,000,000,000.00
Full ELXMF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — ELXMF vs PLD

📍 ELXMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodELXMFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ELXMF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ELXMF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELXMF
Annual income on $10K today (after 15% tax)
$8,947,368.42/yr
After 10yr DRIP, annual income (after tax)
$684,221,949,888,424,200,000,000,000,000,000.00/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, ELXMF beats the other by $684,221,949,888,424,200,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELXMF + PLD for your $10,000?

ELXMF: 50%PLD: 50%
100% PLD50/50100% ELXMF
Portfolio after 10yr
$4.0323565859939053e+26M
Annual income
$402,483,499,934,367,200,000,000,000,000,000.00/yr
Blended yield
99.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ELXMF
No analyst data
Altman Z
-1.9
Piotroski
4/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELXMF buys
0
PLD buys
0
No recent congressional trades found for ELXMF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricELXMFPLD
Forward yield105263.16%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$8.064713171987811e+26M$5.91M
Annual income after 10y$804,966,999,868,734,400,000,000,000,000,000.00$4,750,725.19
Total dividends collected$8.063727433132777e+26M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ELXMF vs PLD ($10,000, DRIP)

YearELXMF PortfolioELXMF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$10,537,016$10,526,315.79$11,241$540.96+$10.53MELXMF
2$10,377,251,773$10,365,977,166.23$13,019$991.13+$10377.24MELXMF
3$9,552,044,282,229$9,540,940,622,831.33$15,801$1,870.97+$9552044.27MELXMF
4$8,217,919,074,277,338$8,207,698,386,895,354.00$20,609$3,701.21+$8217919074.26MELXMF
5$6,608,173,294,209,699,000$6,599,380,120,800,222,000.00$29,919$7,867.97+$6608173294209.67MELXMF
6$4,966,582,566,903,309,000,000$4,959,511,821,478,505,000,000.00$50,631$18,617.74+$4966582566903309.00MELXMF
7$3,488,939,161,660,980,000,000,000$3,483,624,918,314,393,500,000,000.00$105,528$51,352.20+$3488939161660979712.00MELXMF
8$2,290,823,651,613,942,000,000,000,000$2,287,090,486,710,964,800,000,000,000.00$287,364$174,449.42+$2.2908236516139422e+21MELXMF
9$1,405,904,046,772,744,300,000,000,000,000$1,403,452,865,465,517,400,000,000,000,000.00$1,081,760$774,280.77+$1.4059040467727442e+24MELXMF
10$806,471,317,198,781,100,000,000,000,000,000$804,966,999,868,734,400,000,000,000,000,000.00$5,908,209$4,750,725.19+$8.064713171987811e+26MELXMF

ELXMF vs PLD: Complete Analysis 2026

ELXMFStock

Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services surgical devices for the treatment of glaucoma. The company offers iTrack, a surgical system for the reduction in intraocular pressure (IOP) in adult patients with open-angle glaucoma; iTrack Advance, a natural ocular drainage system; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Asia Pacific, and internationally. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was founded in 1985 and is headquartered in Kent Town, Australia.

Full ELXMF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ELXMF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELXMF vs SCHDELXMF vs JEPIELXMF vs OELXMF vs KOELXMF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.